newsfilter
← Latest News
GlobeNewswire·

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments;